MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326991 | Name: Succinobucol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Succinobucol, also known as AGI-1067; AGZ-1067, is phenolic antioxidant with anti-inflammatory and antiplatelet effects and is potentially useful for the treatment of atherosclerosis and type 2 diabetes. Succinobucol displays anti-platelet activity in rabbit and rat blood and reverses the increase in platelet aggregation in response to oxidant stress. Succinobucol induces apoptosis in vascular smooth muscle cells.

Chemical Structure

Succinobucol
Succinobucol
CAS#216167-82-7

Theoretical Analysis

MedKoo Cat#: 326991

Name: Succinobucol

CAS#: 216167-82-7

Chemical Formula: C35H52O5S2

Exact Mass: 616.3256

Molecular Weight: 616.92

Elemental Analysis: C, 68.14; H, 8.50; O, 12.97; S, 10.39

Price and Availability

Size Price Availability Quantity
10mg USD 300.00 2 weeks
25mg USD 530.00 2 weeks
50mg USD 775.00 2 weeks
100mg USD 1,200.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Succinobucol; AGI-1067; AGZ-1067; AGI1067; AGZ1067. Probucol monosuccinae.
IUPAC/Chemical Name
4-(4-((1-((3,5-bis(1,1-Dimethylethyl)-4-hydroxyphenyl)sulfanyl)-1-methylethyl)sulfanyl)-2,6-bis(1,1-dimethylethyl)phenoxy)-4-oxobutanoic acid
InChi Key
RKSMVPNZHBRNNS-UHFFFAOYSA-N
InChi Code
InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37)
SMILES Code
O=C(O)CCC(OC1=C(C(C)(C)C)C=C(SC(C)(SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C)C=C1C(C)(C)C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Succinobucol is a metabolically stable derivative of probucol with diverse biological activities.
In vitro activity:
Succinobucol shows promise in combating atherosclerosis through its antioxidant and anti-inflammatory properties. It exhibits potent lipid peroxide antioxidant activity and enhanced cellular uptake compared to probucol. Succinobucol inhibited ROS levels in endothelial and promonocytic cells, along with suppressing the expression of inflammatory genes. It selectively targets redox-sensitive genes, suggesting its potential as a therapeutic agent against atherosclerosis. Reference: J Pharmacol Exp Ther. 2004 Mar;308(3):820-9. https://pubmed.ncbi.nlm.nih.gov/14617690/
In vivo activity:
Succinobucol could be a potential treatment for early non-motor symptoms and neurodegeneration in Parkinson's disease (PD). In a murine model of PD, mice treated with succinobucol showed improvement in behavioral impairments and neurochemical changes induced by MPTP. Succinobucol did not affect NADH dehydrogenase activity, but did prevent behavioral deficits and neurodegeneration in the substantia nigra and striatum. Succinobucol reduced astroglial activation and increased interleukin-6 levels. Reference: Mol Neurobiol. 2017 Mar;54(2):1513-1530. https://pubmed.ncbi.nlm.nih.gov/26852411/
Solvent mg/mL mM
Solubility
DMF 30.0 48.63
DMSO 30.0 48.63
Ethanol 30.0 48.63
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 616.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Colle D, Santos DB, Hartwig JM, Godoi M, Engel DF, de Bem AF, Braga AL, Farina M. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. Mol Neurobiol. 2016 Mar;53(2):1280-1295. doi: 10.1007/s12035-014-9086-x. Epub 2015 Jan 27. PMID: 25619973. 2. Kunsch C, Luchoomun J, Grey JY, Olliff LK, Saint LB, Arrendale RF, Wasserman MA, Saxena U, Medford RM. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther. 2004 Mar;308(3):820-9. doi: 10.1124/jpet.103.059733. Epub 2003 Nov 14. PMID: 14617690. 3. Santos DB, Colle D, Moreira EL, Hort MA, Godoi M, Le Douaron G, Braga AL, Assreuy J, Michel PP, Prediger RD, Raisman-Vozari R, Farina M. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease. Mol Neurobiol. 2017 Mar;54(2):1513-1530. doi: 10.1007/s12035-016-9747-z. Epub 2016 Feb 6. PMID: 26852411. 4. Sundell CL, Somers PK, Meng CQ, Hoong LK, Suen KL, Hill RR, Landers LK, Chapman A, Butteiger D, Jones M, Edwards D, Daugherty A, Wasserman MA, Alexander RW, Medford RM, Saxena U. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther. 2003 Jun;305(3):1116-23. doi: 10.1124/jpet.102.048132. Epub 2003 Mar 6. PMID: 12626663.
In vitro protocol:
1. Colle D, Santos DB, Hartwig JM, Godoi M, Engel DF, de Bem AF, Braga AL, Farina M. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. Mol Neurobiol. 2016 Mar;53(2):1280-1295. doi: 10.1007/s12035-014-9086-x. Epub 2015 Jan 27. PMID: 25619973. 2. Kunsch C, Luchoomun J, Grey JY, Olliff LK, Saint LB, Arrendale RF, Wasserman MA, Saxena U, Medford RM. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther. 2004 Mar;308(3):820-9. doi: 10.1124/jpet.103.059733. Epub 2003 Nov 14. PMID: 14617690.
In vivo protocol:
1. Santos DB, Colle D, Moreira EL, Hort MA, Godoi M, Le Douaron G, Braga AL, Assreuy J, Michel PP, Prediger RD, Raisman-Vozari R, Farina M. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease. Mol Neurobiol. 2017 Mar;54(2):1513-1530. doi: 10.1007/s12035-016-9747-z. Epub 2016 Feb 6. PMID: 26852411. 2. Sundell CL, Somers PK, Meng CQ, Hoong LK, Suen KL, Hill RR, Landers LK, Chapman A, Butteiger D, Jones M, Edwards D, Daugherty A, Wasserman MA, Alexander RW, Medford RM, Saxena U. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther. 2003 Jun;305(3):1116-23. doi: 10.1124/jpet.102.048132. Epub 2003 Mar 6. PMID: 12626663.
1: Houston SA, Ugusman A, Gnanadesikan S, Kennedy S. An investigation of the antiplatelet effects of succinobucol (AGI-1067). Platelets. 2016 Sep 29:1-6. [Epub ahead of print] PubMed PMID: 27681689. 2: Dan Z, Cao H, He X, Zhang Z, Zou L, Zeng L, Xu Y, Yin Q, Xu M, Zhong D, Yu H, Shen Q, Zhang P, Li Y. A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. Theranostics. 2016 Jan 25;6(3):435-45. doi: 10.7150/thno.13896. eCollection 2016. PubMed PMID: 26909117; PubMed Central PMCID: PMC4737729. 3: Santos DB, Colle D, Moreira EL, Hort MA, Godoi M, Le Douaron G, Braga AL, Assreuy J, Michel PP, Prediger RD, Raisman-Vozari R, Farina M. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease. Mol Neurobiol. 2016 Feb 6. [Epub ahead of print] PubMed PMID: 26852411. 4: Colle D, Santos DB, Hartwig JM, Godoi M, Engel DF, de Bem AF, Braga AL, Farina M. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. Mol Neurobiol. 2016 Mar;53(2):1280-95. doi: 10.1007/s12035-014-9086-x. Epub 2015 Jan 27. PubMed PMID: 25619973. 5: Cao H, Zhang Z, Zhao S, He X, Yu H, Yin Q, Zhang Z, Gu W, Chen L, Li Y. Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression. J Control Release. 2015 May 10;205:162-71. doi: 10.1016/j.jconrel.2015.01.015. Epub 2015 Jan 15. PubMed PMID: 25598420. 6: Colle D, Santos DB, Hartwig JM, Godoi M, Braga AL, Farina M. Succinobucol versus probucol: higher efficiency of succinobucol in mitigating 3-NP-induced brain mitochondrial dysfunction and oxidative stress in vitro. Mitochondrion. 2013 Mar;13(2):125-33. doi: 10.1016/j.mito.2013.01.005. Epub 2013 Jan 17. PubMed PMID: 23333792. 7: Watt J, Kennedy S, McCormick C, Agbani EO, McPhaden A, Mullen A, Czudaj P, Behnisch B, Wadsworth RM, Oldroyd KG. Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model. Catheter Cardiovasc Interv. 2013 Mar;81(4):698-708. doi: 10.1002/ccd.24473. Epub 2012 Nov 8. PubMed PMID: 22581717; PubMed Central PMCID: PMC3600531. 8: Jurček O, Lahtinen M, Wimmer Z, Drašar P, Kolehmainen E. Crystallization, spectral, crystallographical, and thermoanalytical studies of succinobucol polymorphism. J Pharm Sci. 2012 May;101(5):1794-802. doi: 10.1002/jps.23068. Epub 2012 Feb 9. PubMed PMID: 22323097. 9: Midwinter RG, Maghzal GJ, Dennis JM, Wu BJ, Cai H, Kapralov AA, Belikova NA, Tyurina YY, Dong LF, Khachigian L, Neuzil J, Kagan VE, Stocker R. Succinobucol induces apoptosis in vascular smooth muscle cells. Free Radic Biol Med. 2012 Mar 1;52(5):871-9. doi: 10.1016/j.freeradbiomed.2011.11.029. Epub 2011 Dec 21. PubMed PMID: 22203369. 10: Lo MC, Lansang MC. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. Am J Ther. 2013 Nov-Dec;20(6):638-53. doi: 10.1097/MJT.0b013e3181ec9eb2. Review. PubMed PMID: 20838206. 11: Stocker R. Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues. Curr Opin Lipidol. 2009 Jun;20(3):227-35. doi: 10.1097/MOL.0b013e32832aee68. Review. PubMed PMID: 19373083. 12: Muldrew KM, Franks AM. Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects. Expert Opin Investig Drugs. 2009 Apr;18(4):531-9. doi: 10.1517/13543780902849244 . Review. PubMed PMID: 19335281. 13: Liu T, Li G. Probucol and succinobucol in atrial fibrillation: pros and cons. Int J Cardiol. 2010 Oct 8;144(2):295-6. doi: 10.1016/j.ijcard.2009.02.026. Epub 2009 Mar 10. PubMed PMID: 19278740. 14: Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 May 24;371(9626):1761-8. doi: 10.1016/S0140-6736(08)60763-1. PubMed PMID: 18502300. 15: Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, Title LM, Schampaert E, LeMay M, Lespérance J, Scott R, Guertin MC, Brennan ML, Hazen SL, Bertrand OF; CART-2 Investigators. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis. 2008 Mar;197(1):480-6. Epub 2007 Jan 9. PubMed PMID: 17214993.